Johnson & Johnson Change in Inventories 2010-2025 | JNJ

Johnson & Johnson annual/quarterly change in inventories history and growth rate from 2010 to 2025. Change in inventories can be defined as the increase or decrease in a company's inventories for the period.
  • Johnson & Johnson change in inventories for the quarter ending March 31, 2025 was $-0.146B, a 58.05% decline year-over-year.
  • Johnson & Johnson change in inventories for the twelve months ending March 31, 2025 was $-3.051B, a 20.94% decline year-over-year.
  • Johnson & Johnson annual change in inventories for 2024 was $-1.128B, a 14.74% decline from 2023.
  • Johnson & Johnson annual change in inventories for 2023 was $-1.323B, a 47.65% decline from 2022.
  • Johnson & Johnson annual change in inventories for 2022 was $-2.527B, a 102.48% increase from 2021.
Johnson & Johnson Annual Change in Inventories
(Millions of US $)
2024 $-1,128
2023 $-1,323
2022 $-2,527
2021 $-1,248
2020 $-265
2019 $-277
2018 $-644
2017 $581
2016 $-249
2015 $-449
2014 $-1,120
2013 $-622
2012 $-1
2011 $-715
2010 $-196
2009 $95
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $367.191B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $677.821B 51.98
AbbVie (ABBV) United States $322.439B 17.77
Novo Nordisk (NVO) Denmark $305.915B 20.17
Roche Holding AG (RHHBY) Switzerland $249.250B 0.00
Novartis AG (NVS) Switzerland $237.647B 13.57
Merck (MRK) United States $195.459B 9.99
Sanofi (SNY) France $132.654B 12.68
Pfizer (PFE) United States $130.991B 7.18
Bayer (BAYRY) Germany $27.190B 5.54
Innoviva (INVA) United States $1.181B 12.38